Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.62 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.62 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.62 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RORC | P51449 | 1/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565544 | 1.00 | CYP1A2 (0.77) | CYP1A2MAPTALDH1A1AOX1GRIN2D | |
| SCHEMBL13269205 | 1.00 | CYP1A2 (0.77) | CYP1A2MAPTALDH1A1AOX1GRIN2D | |
| SCHEMBL11744328 | 0.87 | MAPT (1.00) | CYP1A2MAPTALDH1A1AOX1GRIN2D | |
| SCHEMBL5075035 | 0.85 | ALDH1A1 (0.62) | CYP1A2MAPTALDH1A1APPMPO | |
| SCHEMBL7990948 | 0.85 | ALDH1A1 (0.62) | CYP1A2MAPTALDH1A1APPMPO | |
| SCHEMBL2568930 | 0.85 | ALDH1A1 (0.62) | CYP1A2MAPTALDH1A1APPMPO | |
| SCHEMBL2165442 | 0.85 | ALDH1A1 (0.65) | CYP1A2MAPTALDH1A1KDM4EGAA | |
| SCHEMBL4345928 | 0.85 | ALDH1A1 (0.65) | CYP1A2MAPTALDH1A1KDM4EGAA | |
| SCHEMBL2165438 | 0.85 | ALDH1A1 (0.65) | CYP1A2MAPTALDH1A1KDM4EGAA | |
| SCHEMBL12756980 | 0.84 | CYP1A2 (0.74) | CYP1A2MAPTALDH1A1AOX1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | claimed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | claimed |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-10-09 | — | — | US | claimed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | claimed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | claimed |
| US-6395260-B1 | SKIN LIGHTENING COMPOSITIONS | HAARMANN & REIMER GMBH (DE) | 2002-05-28 | — | — | US | claimed |
| CN-1279939-A | Local use cosmetic compositions containing benzaldoximes compounds | HAARMANN & REIMER GMBH (DE) | 2001-01-17 | — | — | CN | claimed |
| EP-1066821-A1 | Topical cosmetic product containing benzaldoxims | HAARMANN & REIMER GMBH (DE) | 2001-01-10 | — | — | EP | claimed |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| CN-119899129-A | Compound containing oxime ester structure and preparation method and application thereof | 东北农业大学 | 2025-04-29 | — | — | CN | disclosed |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-11-28 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-06 | — | — | US | disclosed |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007041548-A2 | COMPOSITION FOR REGULATION OF MAMMALIAN KERATINOUS TISSUE | THE PROCTER & GAMBLE COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007001904-A2 | PERSONAL CARE COMPOSITIONS COMPRISING ALPHA-GLUCANS AND/OR BETA-GLUCANS | THE PROCTER & GAMBLE COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-6395260-B1 | SKIN LIGHTENING COMPOSITIONS | HAARMANN & REIMER GMBH (DE) | 2002-05-28 | — | — | US | disclosed |
| CN-1279939-A | Local use cosmetic compositions containing benzaldoximes compounds | HAARMANN & REIMER GMBH (DE) | 2001-01-17 | — | — | CN | disclosed |
| EP-1066821-A1 | Topical cosmetic product containing benzaldoxims | HAARMANN & REIMER GMBH (DE) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | CYP1A2 3186/4885MAPT 1097/4885ALDH1A1 957/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CYP1A2 2166/4885MAPT 497/4885ALDH1A1 371/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | CYP1A2 2789/4885MAPT 143/4885ALDH1A1 1257/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | CYP1A2 1194/4885MAPT 212/4885ALDH1A1 460/4885 |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | INMT, HNMT, CPT1A | CYP1A2 1194/4885MAPT 212/4885ALDH1A1 460/4885 |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | MAVS, IDO2, IDO1 | CYP1A2 362/4885MAPT 302/4885ALDH1A1 1171/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | CYP1A2 1507/4885MAPT 198/4885ALDH1A1 320/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CYP1A2 2166/4885MAPT 497/4885ALDH1A1 371/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | CYP1A2 4193/4885MAPT 1131/4885ALDH1A1 1381/4885 |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | MAVS, IDO2, IDO1 | CYP1A2 392/4885MAPT 415/4885ALDH1A1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.